Amarin: Falls after heart treatment misses main goal in post-marketing study

Matinas BioPharma Holdings

18/11/2019 19:03

** Shares of drugmaker  AMRN.O  slip 6.6% to $22.44, set to
post its worst day in 3 months
    ** AMRN's Vascepa fails to meet a post-marketing study's
main goal of reducing low attenuation plaque, a large, unstable
type of arterial plaque
    ** However, the drug meets secondary goals
    ** Co presented 9-month interim Vascepa data at American
Heart Association scientific conference; study to continue for 9
more months  (http://bit.ly/2r58Zae)
    ** Brokerage Roth Capital Partners says markets are reacting
unfairly as experts emphasized the importance of achieving
secondary goals; Roth says main goal results will likely improve
over rest of trial period
    ** Vascepa, a omega-3 fatty acid-based treatment, won U.S.
approval in 2012 to lower high levels of triglycerides
    ** Last week, FDA expert panel voted unanimously to expand
Vascepa's label based on a separate trial  urn:newsml:reuters.com:*:nL4N27V3E5
    ** Acasti  ACST.O  up 6.9%, and Matinas  MTNB.N  up 20.6%,
are also developing omega-3 fatty acid-based treatment to lower
triglycerides
    ** AMRN has risen 66% YTD 

 (Reporting by Ruhi Soni)
 ((Ruhi.Soni@thomsonreuters.com;))